Key Points
- Prestige VP Jeffrey Zerillo sold 346 shares on May 5 at an average price of $55.32 for about $19,140, leaving him with 44,334 shares; the transaction was executed under a pre-arranged Rule 10b5-1 trading plan (he also sold 1,000 shares on Feb. 11 at $65.93).
- Prestige’s stock has a market cap of $2.56 billion and a PE of 14.34, with a 12‑month range of $51.24–$89.37; the company recently missed quarterly EPS ($1.14 vs. $1.16) and saw revenue decline about 2.4% year‑over‑year.
- Analysts hold a consensus “Hold” rating with a $76.50 target, while institutional investors own roughly 99.95% of the shares and several large funds increased their positions recently.
Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) VP Jeffrey Zerillo sold 346 shares of the firm's stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $55.32, for a total value of $19,140.72. Following the sale, the vice president directly owned 44,334 shares in the company, valued at $2,452,556.88. The trade was a 0.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jeffrey Zerillo also recently made the following trade(s):
- On Wednesday, February 11th, Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock. The stock was sold at an average price of $65.93, for a total value of $65,930.00.
Prestige Consumer Healthcare Stock Performance
Shares of Prestige Consumer Healthcare stock opened at $54.20 on Thursday. The company has a market capitalization of $2.56 billion, a PE ratio of 14.34, a PEG ratio of 1.67 and a beta of 0.40. Prestige Consumer Healthcare Inc. has a 12 month low of $51.24 and a 12 month high of $89.37. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The stock's fifty day simple moving average is $60.52 and its 200 day simple moving average is $61.97.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing the consensus estimate of $1.16 by ($0.02). The business had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business's quarterly revenue was down 2.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.22 EPS. On average, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.54 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Massachusetts Financial Services Co. MA increased its position in shares of Prestige Consumer Healthcare by 10.2% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company's stock worth $40,147,000 after purchasing an additional 60,496 shares during the last quarter. Nordea Investment Management AB boosted its position in Prestige Consumer Healthcare by 547.4% during the fourth quarter. Nordea Investment Management AB now owns 615,215 shares of the company's stock worth $37,811,000 after purchasing an additional 520,186 shares during the period. JPMorgan Chase & Co. boosted its position in Prestige Consumer Healthcare by 30.1% during the third quarter. JPMorgan Chase & Co. now owns 459,228 shares of the company's stock worth $28,656,000 after purchasing an additional 106,224 shares during the period. Allspring Global Investments Holdings LLC boosted its position in Prestige Consumer Healthcare by 1.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company's stock worth $98,776,000 after purchasing an additional 21,085 shares during the period. Finally, Tributary Capital Management LLC boosted its position in Prestige Consumer Healthcare by 157.3% during the third quarter. Tributary Capital Management LLC now owns 379,410 shares of the company's stock worth $23,675,000 after purchasing an additional 231,969 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on PBH. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, April 21st. Jefferies Financial Group cut their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a "hold" rating on the stock in a research note on Friday, January 30th. Three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $76.50.
Get Our Latest Report on PBH
Prestige Consumer Healthcare Company Profile
(
Get Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.
Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
